Good MorningEquity markets advanced on Thursday following an as-expected inflation report. The January PCE Price Index confirmed what the market knew: inflation is accelerating month-to-month and is still hot compared to last year. The good news is that the data aligns with the idea the FOMC is done hiking interest rates. The bad news is that the first interest rate cuts may not come until the 2nd half of the year or later. If that comes to pass, the odds are high that the forecast for this year's S&P 500 earnings growth is wrong.
The S&P 500 is moving higher because the economy is still solid. There are signs of spotty weakness, but the sum is growth. Next week's data includes critical readings on the labor market that may change that outlook, but it is unlikely. Until then, investors should expect consumer spending to remain strong, inflation to be hot, and interest rates to be high. Featured: 25 candidates screened. 5 made it. (Ad) 
|
Technology | |
Investing in crypto stocks involves purchasing shares of companies directly involved in the cryptocurrency industry. Check out our beginner's guide to investing in crypto stocks.
A revolutionary new system for securely and efficiently storing, managing and transferring information, blockchain te... Read the Full Story |
|
From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
|
Consumer Discretionary | |
TJX Companies (NYSE: TJX) rallied strongly over the last few months but peaked following the Q4 release. The post-earnings action forms an ominous candle pattern that could lead to a significant correction. The pattern is a Shooting Star, usually a strong signal of market reversal, but there are m... Read the Full Story |
|
Finance | |
Interested in learning how to invest in Canada? You've landed on the right page. Canadian investment markets aren't as broad or diverse as their neighbors to the south, but there's still plenty of opportunity available in the Great White North.
In this article, you'll learn about the specific typ... Read the Full Story |
|
From Our Partners | | One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate.
Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work. | | Watch the free video to see how the weekly payouts work |
|
Technology | |
Salesforce.com’s (NYSE: CRM) stock price is having trouble with traction following the Q4 results and guidance, but a massive correction is not expected for this tech stock. The results did not catalyze a rally but are good news for investors. The takeaway is that the cloud continues to grow... Read the Full Story |
|
Finance | |
It isn’t often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a pop of more than 100%. Driven by a good story and other factors to help the jump happen.
Inv... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Staples | |
Hormel (NYSE: HRL) shares came under intense pressure last year due to rising costs, margin struggles, and lack of growth. The situation raised doubt about dividend growth, long-term outlooks for profits, and valuation now laid to rest. The Q1 results aren’t mind-boggling but reveal strength... Read the Full Story |
|
Consumer Discretionary | |
Wendy’s Company (NASDAQ: WEN) stock traded nearly 2% higher on February 28 as the fast-food mid-cap said it would not raise prices at times of high demand.
The turnaround came after Wendy’s CEO Kirk Tanner said, in the fourth-quarter earnings conference call, “Beginning as earl... Read the Full Story |
|
Consumer Discretionary | |
Does the recent addition of Amazon Inc. (NASDAQ: AMZN) to the Dow Jones Industrial Average signal that the 30-stock index is still relevant?
And what does the addition mean for Amazon stock?
There's been plenty of debate as to whether the price-weighted Dow is still a relevant market indicator.
... Read the Full Story |
|
Markets | |
Small caps and the iShares Russell 2000 ETF (NYSE: IWM) are marking a notable resurgence, reflecting a significant shift in market sentiment. Over the past three months, the ETF has surged more than 14%, showing resilience even with the year-to-date gain standing at 1.61%. Currently, the ETF is co... Read the Full Story |
|
Consumer Discretionary | |
Some businesses could soon see the bullish side effects of a resilient consumer amongst the pretext of potential interest rate cuts coming this year from the FED. According to the FedWatch tool at the CME Group (NASDAQ: CME), these pivots could be coming as soon as May of this year. However, not a... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
